Clinical trial · Interventional
Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): subject recruitment not feasible due to standard care changes
Summary
Brief summary (as posted)
This is a pilot study to evaluate the efficacy of hyperbaric oxygen therapy (HBO2) for mobilizing hematopoietic progenitor cells from bone marrow to blood. These cells are needed for patients to undergo bone marrow transplantation and some patients fail to respond to current best chemotherapy. HBO2 has been shown to trigger stem cell mobilization in other patient populations and we plan to investigate whether this intervention can act in concert with chemotherapeutic agents to allow poor mobilizer patients to achieve successful bone marrow transplantation. Twenty patients will be identified by participating hematologists who have failed to respond adequately to chemotherapy. When it is deemed appropriate to attempt an additional stem cell mobilization protocol, these patients will be administered chemotherapy as determined by their primary treating hematologist and additionally receive daily HBO2 (2.5 atmospheres absolute \[ATA\] for 90 minutes) for 3-8 days. At intervals, blood samples will be obtained as is the normal transplantation protocol practice to assess whether adequate stem cells are present in blood for the patient to proceed with transplantation. The project is anticipated to take one year to complete.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Marrow Transplantation | — | UNRESOLVED | — |
| Hematopoietic Stem Cells | — | UNRESOLVED | — |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hyperbaric oxygen therapy | Procedure | — | UNRESOLVED |
| Neupogen | Drug | Filgrastim | ALIAS |
| Plerixafor | Drug | Plerixafor | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Hyperbaric oxygen therapy
- description
- Exposure to oxygen at 2.4 atmospheres absolute for 90 minutes/day for 3 to 5 days
- interventionNames
- Drug: Neupogen
- Procedure: Hyperbaric oxygen therapy
- Drug: Plerixafor
Primary outcomes (1)
- measure
- Number of patients who adequately mobilize stem cells to undergo bone marrow transplantation.
- timeFrame
- 1-2 years
- description
- Among entered patients, the number who adequately mobilization of stem cells to proceed with bone marrow transplantation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: 1. Clinical indication for hematopoietic stem cell transplantation. 2. Those failing to achieve an adequate collection of progenitor cells with standard chemotherapy treatment to safely perform hematopoietic stem cell transplantation. Exclusion Criteria: 1. Diabetes mellitus 2. Renal or other organ transplantation and on immunosuppressive agents 3. NYHA Class III or IV heart failure 4. Liver cirrhosis 5. HIV infection and/or AIDS 6. Seizure disorder and not taking anti-seizure medications 7. Asthma/bronchospasm not resolvable with inhaled bronchodilators 8. Eustachian tube dysfunction and inability to equalization of pressure across the middle ears 9. Confinement anxiety not controlled with oral benzodiazepine therapy.
References
Publications (0)
Data not yet available